Treatment with combined dabrafenib and trametinib in BRAFV600E-mutated metastatic malignant melanoma: a case of long-term complete response after treatment cessation

Sonia Brugnara, Mariacristina Sicher, Elena Maria Bonandini, Davide Donner, Franca Chierichetti, Mattia Barbareschi, Carlo Renè Girardelli, Orazio Caffo

Abstract

Here, we report the case of a patient, diagnosed with BRAFV600E-mutated metastatic malignant melanoma M1a, who achieved a complete metabolic response after 7 months of treatment with the combination of dabrafenib and trametinib. After 31 months, the treatment was interrupted for patient’s decision. To date October 2017, 18 months after the interruption of the treatment with the combination of dabrafenib and trametinib, follow-up Positron Emission Tomography (PET) scans are still documenting complete metabolic response.

Article Details

Article Type

Case Report

DOI

10.7573/dic.212515

Publication Dates

Accepted: ; Published: .

Citation

Brugnara S, Sicher M, Bonandini EM, Donner D, Chierichetti F, Barbareschi M, Girardelli CR, Caffo O. Treatment with combined dabrafenib and trametinib in BRAFV600E-mutated metastatic malignant melanoma: a case of long-term complete response after treatment cessation. Drugs in Context 2018; 7: 212515. DOI: 10.7573/dic.212515

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.